FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, a professor at the University of Maryland School of Medicine who formerly served as deputy commissioner for policy at FDA
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
Swedish probiotics player BioGaia is reaping the benefits of increased marketing investments and distribution in the US.
Concerns raised by two recent studies prompt UK researchers to argue for greater regulation with regards to direct-to-consumer test kits.
OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.
